|
**Overview**: **PCOD Comprehensive Profile****Introduction**: The PCOD Comprehensive Profile is a diagnostic tool designed to screen for polycystic ovarian disease using serum samples. Associated with conditions like polycystic ovary syndrome (PCOS), these disorders present with irregular periods, hirsutism, and severe complications if untreated, particularly in individuals with suspected hormonal disorders. Per the 2023 Biochemistry and Endocrinology guidelines, the test employs biochemistry and endocrinology with spectrophotometry and immunoassay technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for hormonal disorder screening in clinical settings. This diagnostic falls under hormonal disorder screening and targets individuals with suspected PCOD, addressing the challenge of accurate hormone assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: PCOD Comp Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry and endocrinology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by endocrinology labs, this test advanced PCOD screening.**Purpose**: The test screens for 18 parameters including LH to guide PCOD assessment, assess hormonal and metabolic status, and inform treatment and prevention strategies.**Test Parameters**: 1. LH, 2. FSH, 3. LH/FSH Ratio, 4. Testosterone Total, 5. Free Testosterone, 6. DHEAS, 7. SHBG, 8. AMH, 9. Prolactin, 10. TSH, 11. Free T4, 12. Insulin, 13. Fasting Glucose, 14. HbA1c, 15. Total Cholesterol, 16. HDL, 17. LDL, 18. Triglycerides.**Pretest Condition**: Fasting 10-12 hours required; patients should report irregular periods, hirsutism, or recent hormonal symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on irregular periods, hirsutism, prior hormonal reactions, or family history of PCOS, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated PCOD including infertility, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry and immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible PCOD, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in endocrinology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Pelvic ultrasound or glucose tolerance test for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in acute illness, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry and Endocrinology Guidelines 2023, Journal of Endocrinology 2024, Chemistry 2025. |
